PL3179986T3 - Suche formulacje w proszku do inhalacji - Google Patents

Suche formulacje w proszku do inhalacji

Info

Publication number
PL3179986T3
PL3179986T3 PL15827152.8T PL15827152T PL3179986T3 PL 3179986 T3 PL3179986 T3 PL 3179986T3 PL 15827152 T PL15827152 T PL 15827152T PL 3179986 T3 PL3179986 T3 PL 3179986T3
Authority
PL
Poland
Prior art keywords
inhalation
dry powder
powder formulations
formulations
dry
Prior art date
Application number
PL15827152.8T
Other languages
English (en)
Inventor
Kambiz Yadidi
Original Assignee
Vectura Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55218356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3179986(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Inc. filed Critical Vectura Inc.
Publication of PL3179986T3 publication Critical patent/PL3179986T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL15827152.8T 2014-07-31 2015-07-31 Suche formulacje w proszku do inhalacji PL3179986T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462031811P 2014-07-31 2014-07-31
PCT/US2015/043128 WO2016019253A1 (en) 2014-07-31 2015-07-31 Dry powder formulations for inhalation

Publications (1)

Publication Number Publication Date
PL3179986T3 true PL3179986T3 (pl) 2023-06-26

Family

ID=55218356

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15827152.8T PL3179986T3 (pl) 2014-07-31 2015-07-31 Suche formulacje w proszku do inhalacji

Country Status (10)

Country Link
EP (2) EP4218734A1 (pl)
JP (1) JP6850524B2 (pl)
KR (2) KR102666667B1 (pl)
CN (2) CN116687887A (pl)
AU (2) AU2015296142A1 (pl)
CA (1) CA2991760C (pl)
DK (1) DK3179986T3 (pl)
ES (1) ES2942297T3 (pl)
PL (1) PL3179986T3 (pl)
WO (1) WO2016019253A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176552A1 (en) * 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
EP3463378A4 (en) 2016-06-03 2020-01-08 Otitopic Inc. DRY POWDER FORMULAS FOR INHALATION
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CA3076353A1 (en) * 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
EP4311566A1 (en) 2022-07-28 2024-01-31 Vectura Inc. An inhaler comprising a retention element
KR20260081332A (ko) 2024-11-25 2026-06-04 충북대학교 산학협력단 머신 러닝 기반 건조분말 흡입제제의 흡입 효율 예측 시스템 및 방법

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
AU706195B2 (en) 1995-04-14 1999-06-10 Inhale Therapeutic Systems Powdered pharmaceutical formulations having improved dispersibility
MX9707862A (es) 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida para el propionato de fluticasona.
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
WO1998055104A1 (fr) * 1997-06-06 1998-12-10 Shionogi & Co., Ltd. Perfectionnement d'un systeme d'administration de medicament
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
ATE248583T1 (de) 1997-09-29 2003-09-15 Nektar Therapeutics In dosierinhalatoren verwendbare, stabilisierte zubereitungen
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
WO2000000215A1 (en) 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ES2292598T3 (es) * 2000-06-27 2008-03-16 Vectura Limited Metodo para producir particulas para usar en una composicion farmaceutica.
CA2465675C (en) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US20080044481A1 (en) 2004-05-27 2008-02-21 Mordechai Harel Microparticles for Oral Delivery
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
AU2006230242B2 (en) 2005-03-28 2013-05-30 Pericor Therapeutics, Inc. Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
EP1898911A1 (en) * 2005-06-13 2008-03-19 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
GB0621957D0 (en) * 2006-11-03 2006-12-13 Vectura Group Plc Inhaler devices and bespoke pharmaceutical compositions
WO2009026434A1 (en) 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
EP2252275B1 (en) 2008-02-13 2017-11-29 Board of Regents, The University of Texas System Templated open flocs of anisotropic particles for enhanced pulmonary delivery
CA2759109A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
GB201102237D0 (en) * 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
US9216527B2 (en) 2012-02-09 2015-12-22 G & W Electric Company Solid-dielectric switch including a molded viewing window
CN107875127A (zh) 2012-02-28 2018-04-06 艾塞尤提卡控股公司 可吸入药物组合物
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN105473133A (zh) * 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
EP3107548B8 (en) 2014-02-20 2022-07-20 Otitopic Inc. Dry powder formulations for inhalation

Also Published As

Publication number Publication date
KR102603897B1 (ko) 2023-11-20
KR102666667B1 (ko) 2024-05-17
CA2991760C (en) 2025-05-06
DK3179986T3 (da) 2023-05-01
EP3179986A1 (en) 2017-06-21
EP4218734A1 (en) 2023-08-02
CN107072947A (zh) 2017-08-18
EP3179986B1 (en) 2023-03-15
WO2016019253A1 (en) 2016-02-04
KR20170039255A (ko) 2017-04-10
ES2942297T3 (es) 2023-05-31
JP6850524B2 (ja) 2021-03-31
EP3179986A4 (en) 2018-02-07
WO2016019253A9 (en) 2016-05-12
JP2017523189A (ja) 2017-08-17
KR20230119032A (ko) 2023-08-14
AU2020203437B2 (en) 2020-09-17
AU2015296142A1 (en) 2017-02-23
CA2991760A1 (en) 2016-02-04
AU2020203437A1 (en) 2020-06-11
CN116687887A (zh) 2023-09-05

Similar Documents

Publication Publication Date Title
PL3107548T3 (pl) Suche formulacje w proszku do inhalacji
ZA201606073B (en) Nicotine powder inhaler
ZA201703077B (en) Dry powder inhaler
PT3240415T (pt) Composições fungicidas
IL257004B (en) Dry powder inhaler
GB2522492B (en) Dry powder processing
LT3505209T (lt) Miltelių inhaliatorius
GB201419091D0 (en) Formulations
PL3138601T3 (pl) Inhalator suchego proszku
IL263365A (en) Dry powder inhaler
GB201419261D0 (en) Formulations
EP3179986A4 (en) Dry powder formulations for inhalation
IL251665A0 (en) Dry powder formulation
GB2542283B (en) Dry powder fire-fighting composition
IL249773A0 (en) Breaks up lumps of dry powder medicine
IL249774A0 (en) Dry powder nebulizer
IL249398A0 (en) A dry powder inhaler that is activated by breathing
GB201511942D0 (en) Dry powder inhaler apparatus
ZA201702717B (en) Powder formulation
HK1240151A1 (en) Dry powder inhaler
GB201511950D0 (en) Dry powder inhaler apparatus
IL247557A0 (en) Nicotine powder inhaler
HK1230118A1 (en) Dry powder inhaler
HK1243010A1 (en) Dry powder medicament de-agglomerator
HK1238585A1 (en) Dry powder nebulizer